Review



melatonin receptor mtnr1b specific antagonist 4 p pdot  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress melatonin receptor mtnr1b specific antagonist 4 p pdot
    Fig. 1. Effects of <t>Mtnr1b</t> knockout in mice on placental functions. (a) Mtnr1b knockout murine construction strategy. (b) PCR results of Mtnr1b knockout at the genomic level. (c) The mRNA expression levels in placental tissues (n = 4). (d) The average litter size (n = 4). (e) Photograph of feta size at day 18 of gestation. (f) The average of fetal weight (n = 33). (g) The average of placental weight (n = 33). (h) The average of placental diameter (n = 33). (i) The average of placental efficiency (n = 33). Data are presented as means ± SEM. * p < 0.05. *** p < 0.001.
    Melatonin Receptor Mtnr1b Specific Antagonist 4 P Pdot, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/melatonin+receptor+antagonist+4+p+pdot/4-P-PDOT/pm38960012-56-7-20
    Average 94 stars, based on 24 article reviews
    melatonin receptor mtnr1b specific antagonist 4 p pdot - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Mtnr1b deletion disrupts placental angiogenesis through the VEGF signaling pathway leading to fetal growth restriction."

    Article Title: Mtnr1b deletion disrupts placental angiogenesis through the VEGF signaling pathway leading to fetal growth restriction.

    Journal: Pharmacological research

    doi: 10.1016/j.phrs.2024.107290

    Fig. 1. Effects of Mtnr1b knockout in mice on placental functions. (a) Mtnr1b knockout murine construction strategy. (b) PCR results of Mtnr1b knockout at the genomic level. (c) The mRNA expression levels in placental tissues (n = 4). (d) The average litter size (n = 4). (e) Photograph of feta size at day 18 of gestation. (f) The average of fetal weight (n = 33). (g) The average of placental weight (n = 33). (h) The average of placental diameter (n = 33). (i) The average of placental efficiency (n = 33). Data are presented as means ± SEM. * p < 0.05. *** p < 0.001.
    Figure Legend Snippet: Fig. 1. Effects of Mtnr1b knockout in mice on placental functions. (a) Mtnr1b knockout murine construction strategy. (b) PCR results of Mtnr1b knockout at the genomic level. (c) The mRNA expression levels in placental tissues (n = 4). (d) The average litter size (n = 4). (e) Photograph of feta size at day 18 of gestation. (f) The average of fetal weight (n = 33). (g) The average of placental weight (n = 33). (h) The average of placental diameter (n = 33). (i) The average of placental efficiency (n = 33). Data are presented as means ± SEM. * p < 0.05. *** p < 0.001.

    Techniques Used: Knock-Out, Expressing

    Fig. 2. Effects of Mtnr1b knockout in mice on placental apoptosis and antioxidant enzymes. (a) Placental tissue’s TUNEL staining. Scale Bar = 100 μm. (b) The average of fluorescence intensity (apoptotic staining) was statistically analyzed with Image J software (n = 3). (c, d) The expression levels of apoptosis related proteins Cleaved-caspase3 and Bcl-2 in placental tissues (n = 4). (e, f) The expression levels of antioxidant enzymes of Cat and HO-1 in placenta tissues (n = 4). Data are presented as means ± SEM. * p < 0.05. ** p < 0.01.
    Figure Legend Snippet: Fig. 2. Effects of Mtnr1b knockout in mice on placental apoptosis and antioxidant enzymes. (a) Placental tissue’s TUNEL staining. Scale Bar = 100 μm. (b) The average of fluorescence intensity (apoptotic staining) was statistically analyzed with Image J software (n = 3). (c, d) The expression levels of apoptosis related proteins Cleaved-caspase3 and Bcl-2 in placental tissues (n = 4). (e, f) The expression levels of antioxidant enzymes of Cat and HO-1 in placenta tissues (n = 4). Data are presented as means ± SEM. * p < 0.05. ** p < 0.01.

    Techniques Used: Knock-Out, TUNEL Assay, Staining, Fluorescence, Software, Expressing

    Fig. 4. Effects of Mtnr1b knockout in mice on placental angiogenesis. (a) The mRNA levels of angiogenesis related factors (n = 4). (b) The mRNA levels of VEGF receptors (n = 4). (c-h) The protein expression levels of VEGFR2, p-AKT and eNOS3 in placenta tissues (n = 4). Data are presented as means ± SEM. * p < 0.05. ** p < 0.01.
    Figure Legend Snippet: Fig. 4. Effects of Mtnr1b knockout in mice on placental angiogenesis. (a) The mRNA levels of angiogenesis related factors (n = 4). (b) The mRNA levels of VEGF receptors (n = 4). (c-h) The protein expression levels of VEGFR2, p-AKT and eNOS3 in placenta tissues (n = 4). Data are presented as means ± SEM. * p < 0.05. ** p < 0.01.

    Techniques Used: Knock-Out, Expressing

    Fig. 7. Effects of melatonergic system on STAT3/VEGFR2 pathway. (a) The mRNA expression levels of VEGFR2 upon STAT3 activation (n = 3). (b, c) Western blotting was used to detect the expression levels of VEGFR2 and p-STAT3 after STAT3 phosphorylation activation, (n = 3). (d) The mRNA expression levels of VEGFR2 upon inhibition of STAT3 activation (n = 3). (e, f) Western blotting was used to detect the expression levels of VEGFR2 and p-STAT3 after inhibition of STAT3 activation, (n = 3). (g, h) The protein level of VEGFR2 was detected by supplementing STAT3 after MTNR1B inhibition, (n = 3). (i, j) The expression level of p- STAT3 in mouse placenta was detected by Western blotting (n = 4). (k, l) Western blotting was used to detect the expression level of p-STAT3 in porcine placenta (n = 3). Data are presented as means ± SEM. * means p < 0.05. *** means p < 0.001.
    Figure Legend Snippet: Fig. 7. Effects of melatonergic system on STAT3/VEGFR2 pathway. (a) The mRNA expression levels of VEGFR2 upon STAT3 activation (n = 3). (b, c) Western blotting was used to detect the expression levels of VEGFR2 and p-STAT3 after STAT3 phosphorylation activation, (n = 3). (d) The mRNA expression levels of VEGFR2 upon inhibition of STAT3 activation (n = 3). (e, f) Western blotting was used to detect the expression levels of VEGFR2 and p-STAT3 after inhibition of STAT3 activation, (n = 3). (g, h) The protein level of VEGFR2 was detected by supplementing STAT3 after MTNR1B inhibition, (n = 3). (i, j) The expression level of p- STAT3 in mouse placenta was detected by Western blotting (n = 4). (k, l) Western blotting was used to detect the expression level of p-STAT3 in porcine placenta (n = 3). Data are presented as means ± SEM. * means p < 0.05. *** means p < 0.001.

    Techniques Used: Expressing, Activation Assay, Western Blot, Phospho-proteomics, Inhibition

    Related Articles

    Incubation:

    Article Title: Melatonin Alleviates Lipopolysaccharide-Induced Abnormal Pregnancy through MTNR1B Regulation of m6A.
    Article Snippet: Cells were cultured in DMEMB/F12 (Gibco, Grand Island, NE, USA) containing 10% FBS (Gibco, Grand Island, NE, USA). .. Once cells were attached, HESCs were starved for 12 h in DMEM/F12, cells were treated with 1 μM Melatonin and 50 μg/mL LPS for 48 h. For experiments involving inhibitors, cells were incubated with inhibitors for 48 h. The following specific inhibitors were used: melatonin receptor antagonist 4-P-PDOT (MedChemExpress, Monmouth Junction, NJ, USA), and the METTL3-METTL14 complex inhibitor SAH (MCE, Monmouth Junction, NJ, USA). ..

    Article Title: Melatonin alleviates LPS-induced abnormal pregnancy through MTNR1B regulation of m6A
    Article Snippet: .. Once cells were attached, HESCs were starved for 12 h in DMEM/F12, cells were treated with 1 μM Melatonin and 50 μg/mL LPS for 48 h. For experiments involving inhibitors, cells were incubated with inhibitor for 48 h. The following specific inhibitors were used: melatonin receptor antagonist 4-P-PDOT (MCE, NJ, USA) and the METTL3-METTL14 complex inhibitor SAH (MCE, NJ, USA). ..

    Article Title: Melatonin Alleviates Lipopolysaccharide-Induced Abnormal Pregnancy through MTNR1B Regulation of m6A
    Article Snippet: Cells were cultured in DMEMB/F12 (Gibco, Grand Island, NE, USA) containing 10% FBS (Gibco, Grand Island, NE, USA). .. Once cells were attached, HESCs were starved for 12 h in DMEM/F12, cells were treated with 1 μM Melatonin and 50 μg/mL LPS for 48 h. For experiments involving inhibitors, cells were incubated with inhibitors for 48 h. The following specific inhibitors were used: melatonin receptor antagonist 4-P-PDOT (MedChemExpress, Monmouth Junction, NJ, USA), and the METTL3-METTL14 complex inhibitor SAH (MCE, Monmouth Junction, NJ, USA). ..



    Similar Products

    93
    Tocris selective melatonin mt2 receptor antagonist
    Selective Melatonin Mt2 Receptor Antagonist, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/melatonin+receptor+antagonist+4+p+pdot/4-P-PDOT/pm40752763-78-4-22
    Average 93 stars, based on 1 article reviews
    selective melatonin mt2 receptor antagonist - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    MedChemExpress melatonin receptor mtnr1b specific antagonist 4 p pdot
    Fig. 1. Effects of <t>Mtnr1b</t> knockout in mice on placental functions. (a) Mtnr1b knockout murine construction strategy. (b) PCR results of Mtnr1b knockout at the genomic level. (c) The mRNA expression levels in placental tissues (n = 4). (d) The average litter size (n = 4). (e) Photograph of feta size at day 18 of gestation. (f) The average of fetal weight (n = 33). (g) The average of placental weight (n = 33). (h) The average of placental diameter (n = 33). (i) The average of placental efficiency (n = 33). Data are presented as means ± SEM. * p < 0.05. *** p < 0.001.
    Melatonin Receptor Mtnr1b Specific Antagonist 4 P Pdot, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/melatonin+receptor+antagonist+4+p+pdot/4-P-PDOT/pm38960012-56-7-20
    Average 94 stars, based on 1 article reviews
    melatonin receptor mtnr1b specific antagonist 4 p pdot - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress mt2 selective melatonin receptor antagonist 4p pdot
    Fig. 1. Effects of <t>Mtnr1b</t> knockout in mice on placental functions. (a) Mtnr1b knockout murine construction strategy. (b) PCR results of Mtnr1b knockout at the genomic level. (c) The mRNA expression levels in placental tissues (n = 4). (d) The average litter size (n = 4). (e) Photograph of feta size at day 18 of gestation. (f) The average of fetal weight (n = 33). (g) The average of placental weight (n = 33). (h) The average of placental diameter (n = 33). (i) The average of placental efficiency (n = 33). Data are presented as means ± SEM. * p < 0.05. *** p < 0.001.
    Mt2 Selective Melatonin Receptor Antagonist 4p Pdot, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/melatonin+receptor+antagonist+4+p+pdot/4-P-PDOT/pmc11169869-66-10-16
    Average 94 stars, based on 1 article reviews
    mt2 selective melatonin receptor antagonist 4p pdot - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress melatonin receptor antagonist 4 p pdot
    Figure 7. Melatonin plays a protective role through MTNR1B. (A) Cell proliferation assay by CCK8 method. n = 6 independent biological replicates. <t>4-P-PDOT:</t> 4-phenyl-2-propionamidotetralin; SAH: S-adenosylhomocysteine; * Indicates a significant difference compared with the 4-P-PDOT/SAH 0 µM group; * p < 0.05; ** p < 0.01; *** p < 0.001; # Indicates a significant difference compared with the LPS added group alone Difference; # p < 0.05; ## p < 0.01; ### p < 0.001. (B) Global m6A levels of human endometrial stromal cells treated with 4PPDOT. (C) Western blot bands of inflammation- related proteins in human endometrial stromal cells. (D) Immunoblot analysis of p-RELA, RELA, ERK1/2. (E) Western blot bands of autophagy related proteins in human endometrial stromal cells. (F) Immunoblot analysis of LC3B, ATG5, ATG7. (G) Western blot bands of apoptosis related proteins in human endometrial stromal cells. (H) Immunoblot analysis of c-PARP, BAX, CASP1, c-CASP3. (I) Flow cytometry was used to detect apoptosis after adding the 4PPDOT and melatonin, and apoptosis cells were measured. n = 3 independent biological replicates. Veh: vehicle treatment group; LPS: LPS treatment group; Mel+LPS: melatonin and LPS co-treatment group; Mel: melatonin treatment group; The data are presented as the mean ± SD. Levels of statistical significance for all data were determined by one-way ANOVA and Tukey’s test (* Indicates significant difference between the two groups; * p < 0.05; ** p < 0.01; *** p < 0.001).
    Melatonin Receptor Antagonist 4 P Pdot, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/melatonin+receptor+antagonist+4+p+pdot/4-P-PDOT/pm38255808-276-44-48
    Average 94 stars, based on 1 article reviews
    melatonin receptor antagonist 4 p pdot - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    Tocris melatonin receptor antagonist 4p pdot
    Figure 7. Melatonin plays a protective role through MTNR1B. (A) Cell proliferation assay by CCK8 method. n = 6 independent biological replicates. <t>4-P-PDOT:</t> 4-phenyl-2-propionamidotetralin; SAH: S-adenosylhomocysteine; * Indicates a significant difference compared with the 4-P-PDOT/SAH 0 µM group; * p < 0.05; ** p < 0.01; *** p < 0.001; # Indicates a significant difference compared with the LPS added group alone Difference; # p < 0.05; ## p < 0.01; ### p < 0.001. (B) Global m6A levels of human endometrial stromal cells treated with 4PPDOT. (C) Western blot bands of inflammation- related proteins in human endometrial stromal cells. (D) Immunoblot analysis of p-RELA, RELA, ERK1/2. (E) Western blot bands of autophagy related proteins in human endometrial stromal cells. (F) Immunoblot analysis of LC3B, ATG5, ATG7. (G) Western blot bands of apoptosis related proteins in human endometrial stromal cells. (H) Immunoblot analysis of c-PARP, BAX, CASP1, c-CASP3. (I) Flow cytometry was used to detect apoptosis after adding the 4PPDOT and melatonin, and apoptosis cells were measured. n = 3 independent biological replicates. Veh: vehicle treatment group; LPS: LPS treatment group; Mel+LPS: melatonin and LPS co-treatment group; Mel: melatonin treatment group; The data are presented as the mean ± SD. Levels of statistical significance for all data were determined by one-way ANOVA and Tukey’s test (* Indicates significant difference between the two groups; * p < 0.05; ** p < 0.01; *** p < 0.001).
    Melatonin Receptor Antagonist 4p Pdot, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/melatonin+receptor+antagonist+4+p+pdot/4-P-PDOT/pm35396993-53-15-20
    Average 93 stars, based on 1 article reviews
    melatonin receptor antagonist 4p pdot - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    Tocris melatonin 2 mt2 receptor antagonist 4p pdot
    Figure 7. Melatonin plays a protective role through MTNR1B. (A) Cell proliferation assay by CCK8 method. n = 6 independent biological replicates. <t>4-P-PDOT:</t> 4-phenyl-2-propionamidotetralin; SAH: S-adenosylhomocysteine; * Indicates a significant difference compared with the 4-P-PDOT/SAH 0 µM group; * p < 0.05; ** p < 0.01; *** p < 0.001; # Indicates a significant difference compared with the LPS added group alone Difference; # p < 0.05; ## p < 0.01; ### p < 0.001. (B) Global m6A levels of human endometrial stromal cells treated with 4PPDOT. (C) Western blot bands of inflammation- related proteins in human endometrial stromal cells. (D) Immunoblot analysis of p-RELA, RELA, ERK1/2. (E) Western blot bands of autophagy related proteins in human endometrial stromal cells. (F) Immunoblot analysis of LC3B, ATG5, ATG7. (G) Western blot bands of apoptosis related proteins in human endometrial stromal cells. (H) Immunoblot analysis of c-PARP, BAX, CASP1, c-CASP3. (I) Flow cytometry was used to detect apoptosis after adding the 4PPDOT and melatonin, and apoptosis cells were measured. n = 3 independent biological replicates. Veh: vehicle treatment group; LPS: LPS treatment group; Mel+LPS: melatonin and LPS co-treatment group; Mel: melatonin treatment group; The data are presented as the mean ± SD. Levels of statistical significance for all data were determined by one-way ANOVA and Tukey’s test (* Indicates significant difference between the two groups; * p < 0.05; ** p < 0.01; *** p < 0.001).
    Melatonin 2 Mt2 Receptor Antagonist 4p Pdot, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/melatonin+receptor+antagonist+4+p+pdot/4-P-PDOT/10__1016_slash_j__jembe__2011__05__033-31-3-9
    Average 94 stars, based on 1 article reviews
    melatonin 2 mt2 receptor antagonist 4p pdot - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    Tocris melatonin receptor antagonist 4 phenyl 2 propionamidotetralin
    Figure 7. Melatonin plays a protective role through MTNR1B. (A) Cell proliferation assay by CCK8 method. n = 6 independent biological replicates. <t>4-P-PDOT:</t> 4-phenyl-2-propionamidotetralin; SAH: S-adenosylhomocysteine; * Indicates a significant difference compared with the 4-P-PDOT/SAH 0 µM group; * p < 0.05; ** p < 0.01; *** p < 0.001; # Indicates a significant difference compared with the LPS added group alone Difference; # p < 0.05; ## p < 0.01; ### p < 0.001. (B) Global m6A levels of human endometrial stromal cells treated with 4PPDOT. (C) Western blot bands of inflammation- related proteins in human endometrial stromal cells. (D) Immunoblot analysis of p-RELA, RELA, ERK1/2. (E) Western blot bands of autophagy related proteins in human endometrial stromal cells. (F) Immunoblot analysis of LC3B, ATG5, ATG7. (G) Western blot bands of apoptosis related proteins in human endometrial stromal cells. (H) Immunoblot analysis of c-PARP, BAX, CASP1, c-CASP3. (I) Flow cytometry was used to detect apoptosis after adding the 4PPDOT and melatonin, and apoptosis cells were measured. n = 3 independent biological replicates. Veh: vehicle treatment group; LPS: LPS treatment group; Mel+LPS: melatonin and LPS co-treatment group; Mel: melatonin treatment group; The data are presented as the mean ± SD. Levels of statistical significance for all data were determined by one-way ANOVA and Tukey’s test (* Indicates significant difference between the two groups; * p < 0.05; ** p < 0.01; *** p < 0.001).
    Melatonin Receptor Antagonist 4 Phenyl 2 Propionamidotetralin, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/melatonin+receptor+antagonist+4+p+pdot/4-P-PDOT/pm12574232-68-11-16
    Average 94 stars, based on 1 article reviews
    melatonin receptor antagonist 4 phenyl 2 propionamidotetralin - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 1. Effects of Mtnr1b knockout in mice on placental functions. (a) Mtnr1b knockout murine construction strategy. (b) PCR results of Mtnr1b knockout at the genomic level. (c) The mRNA expression levels in placental tissues (n = 4). (d) The average litter size (n = 4). (e) Photograph of feta size at day 18 of gestation. (f) The average of fetal weight (n = 33). (g) The average of placental weight (n = 33). (h) The average of placental diameter (n = 33). (i) The average of placental efficiency (n = 33). Data are presented as means ± SEM. * p < 0.05. *** p < 0.001.

    Journal: Pharmacological research

    Article Title: Mtnr1b deletion disrupts placental angiogenesis through the VEGF signaling pathway leading to fetal growth restriction.

    doi: 10.1016/j.phrs.2024.107290

    Figure Lengend Snippet: Fig. 1. Effects of Mtnr1b knockout in mice on placental functions. (a) Mtnr1b knockout murine construction strategy. (b) PCR results of Mtnr1b knockout at the genomic level. (c) The mRNA expression levels in placental tissues (n = 4). (d) The average litter size (n = 4). (e) Photograph of feta size at day 18 of gestation. (f) The average of fetal weight (n = 33). (g) The average of placental weight (n = 33). (h) The average of placental diameter (n = 33). (i) The average of placental efficiency (n = 33). Data are presented as means ± SEM. * p < 0.05. *** p < 0.001.

    Article Snippet: The STAT3 activation inhibitor stattic (HY-13818) and melatonin receptor MTNR1B specific antagonist 4 P-PDOT (HY-100609) were purchased from the Chinese MCE company (Shanghai, China).

    Techniques: Knock-Out, Expressing

    Fig. 2. Effects of Mtnr1b knockout in mice on placental apoptosis and antioxidant enzymes. (a) Placental tissue’s TUNEL staining. Scale Bar = 100 μm. (b) The average of fluorescence intensity (apoptotic staining) was statistically analyzed with Image J software (n = 3). (c, d) The expression levels of apoptosis related proteins Cleaved-caspase3 and Bcl-2 in placental tissues (n = 4). (e, f) The expression levels of antioxidant enzymes of Cat and HO-1 in placenta tissues (n = 4). Data are presented as means ± SEM. * p < 0.05. ** p < 0.01.

    Journal: Pharmacological research

    Article Title: Mtnr1b deletion disrupts placental angiogenesis through the VEGF signaling pathway leading to fetal growth restriction.

    doi: 10.1016/j.phrs.2024.107290

    Figure Lengend Snippet: Fig. 2. Effects of Mtnr1b knockout in mice on placental apoptosis and antioxidant enzymes. (a) Placental tissue’s TUNEL staining. Scale Bar = 100 μm. (b) The average of fluorescence intensity (apoptotic staining) was statistically analyzed with Image J software (n = 3). (c, d) The expression levels of apoptosis related proteins Cleaved-caspase3 and Bcl-2 in placental tissues (n = 4). (e, f) The expression levels of antioxidant enzymes of Cat and HO-1 in placenta tissues (n = 4). Data are presented as means ± SEM. * p < 0.05. ** p < 0.01.

    Article Snippet: The STAT3 activation inhibitor stattic (HY-13818) and melatonin receptor MTNR1B specific antagonist 4 P-PDOT (HY-100609) were purchased from the Chinese MCE company (Shanghai, China).

    Techniques: Knock-Out, TUNEL Assay, Staining, Fluorescence, Software, Expressing

    Fig. 4. Effects of Mtnr1b knockout in mice on placental angiogenesis. (a) The mRNA levels of angiogenesis related factors (n = 4). (b) The mRNA levels of VEGF receptors (n = 4). (c-h) The protein expression levels of VEGFR2, p-AKT and eNOS3 in placenta tissues (n = 4). Data are presented as means ± SEM. * p < 0.05. ** p < 0.01.

    Journal: Pharmacological research

    Article Title: Mtnr1b deletion disrupts placental angiogenesis through the VEGF signaling pathway leading to fetal growth restriction.

    doi: 10.1016/j.phrs.2024.107290

    Figure Lengend Snippet: Fig. 4. Effects of Mtnr1b knockout in mice on placental angiogenesis. (a) The mRNA levels of angiogenesis related factors (n = 4). (b) The mRNA levels of VEGF receptors (n = 4). (c-h) The protein expression levels of VEGFR2, p-AKT and eNOS3 in placenta tissues (n = 4). Data are presented as means ± SEM. * p < 0.05. ** p < 0.01.

    Article Snippet: The STAT3 activation inhibitor stattic (HY-13818) and melatonin receptor MTNR1B specific antagonist 4 P-PDOT (HY-100609) were purchased from the Chinese MCE company (Shanghai, China).

    Techniques: Knock-Out, Expressing

    Fig. 7. Effects of melatonergic system on STAT3/VEGFR2 pathway. (a) The mRNA expression levels of VEGFR2 upon STAT3 activation (n = 3). (b, c) Western blotting was used to detect the expression levels of VEGFR2 and p-STAT3 after STAT3 phosphorylation activation, (n = 3). (d) The mRNA expression levels of VEGFR2 upon inhibition of STAT3 activation (n = 3). (e, f) Western blotting was used to detect the expression levels of VEGFR2 and p-STAT3 after inhibition of STAT3 activation, (n = 3). (g, h) The protein level of VEGFR2 was detected by supplementing STAT3 after MTNR1B inhibition, (n = 3). (i, j) The expression level of p- STAT3 in mouse placenta was detected by Western blotting (n = 4). (k, l) Western blotting was used to detect the expression level of p-STAT3 in porcine placenta (n = 3). Data are presented as means ± SEM. * means p < 0.05. *** means p < 0.001.

    Journal: Pharmacological research

    Article Title: Mtnr1b deletion disrupts placental angiogenesis through the VEGF signaling pathway leading to fetal growth restriction.

    doi: 10.1016/j.phrs.2024.107290

    Figure Lengend Snippet: Fig. 7. Effects of melatonergic system on STAT3/VEGFR2 pathway. (a) The mRNA expression levels of VEGFR2 upon STAT3 activation (n = 3). (b, c) Western blotting was used to detect the expression levels of VEGFR2 and p-STAT3 after STAT3 phosphorylation activation, (n = 3). (d) The mRNA expression levels of VEGFR2 upon inhibition of STAT3 activation (n = 3). (e, f) Western blotting was used to detect the expression levels of VEGFR2 and p-STAT3 after inhibition of STAT3 activation, (n = 3). (g, h) The protein level of VEGFR2 was detected by supplementing STAT3 after MTNR1B inhibition, (n = 3). (i, j) The expression level of p- STAT3 in mouse placenta was detected by Western blotting (n = 4). (k, l) Western blotting was used to detect the expression level of p-STAT3 in porcine placenta (n = 3). Data are presented as means ± SEM. * means p < 0.05. *** means p < 0.001.

    Article Snippet: The STAT3 activation inhibitor stattic (HY-13818) and melatonin receptor MTNR1B specific antagonist 4 P-PDOT (HY-100609) were purchased from the Chinese MCE company (Shanghai, China).

    Techniques: Expressing, Activation Assay, Western Blot, Phospho-proteomics, Inhibition

    Figure 7. Melatonin plays a protective role through MTNR1B. (A) Cell proliferation assay by CCK8 method. n = 6 independent biological replicates. 4-P-PDOT: 4-phenyl-2-propionamidotetralin; SAH: S-adenosylhomocysteine; * Indicates a significant difference compared with the 4-P-PDOT/SAH 0 µM group; * p < 0.05; ** p < 0.01; *** p < 0.001; # Indicates a significant difference compared with the LPS added group alone Difference; # p < 0.05; ## p < 0.01; ### p < 0.001. (B) Global m6A levels of human endometrial stromal cells treated with 4PPDOT. (C) Western blot bands of inflammation- related proteins in human endometrial stromal cells. (D) Immunoblot analysis of p-RELA, RELA, ERK1/2. (E) Western blot bands of autophagy related proteins in human endometrial stromal cells. (F) Immunoblot analysis of LC3B, ATG5, ATG7. (G) Western blot bands of apoptosis related proteins in human endometrial stromal cells. (H) Immunoblot analysis of c-PARP, BAX, CASP1, c-CASP3. (I) Flow cytometry was used to detect apoptosis after adding the 4PPDOT and melatonin, and apoptosis cells were measured. n = 3 independent biological replicates. Veh: vehicle treatment group; LPS: LPS treatment group; Mel+LPS: melatonin and LPS co-treatment group; Mel: melatonin treatment group; The data are presented as the mean ± SD. Levels of statistical significance for all data were determined by one-way ANOVA and Tukey’s test (* Indicates significant difference between the two groups; * p < 0.05; ** p < 0.01; *** p < 0.001).

    Journal: International journal of molecular sciences

    Article Title: Melatonin Alleviates Lipopolysaccharide-Induced Abnormal Pregnancy through MTNR1B Regulation of m6A.

    doi: 10.3390/ijms25020733

    Figure Lengend Snippet: Figure 7. Melatonin plays a protective role through MTNR1B. (A) Cell proliferation assay by CCK8 method. n = 6 independent biological replicates. 4-P-PDOT: 4-phenyl-2-propionamidotetralin; SAH: S-adenosylhomocysteine; * Indicates a significant difference compared with the 4-P-PDOT/SAH 0 µM group; * p < 0.05; ** p < 0.01; *** p < 0.001; # Indicates a significant difference compared with the LPS added group alone Difference; # p < 0.05; ## p < 0.01; ### p < 0.001. (B) Global m6A levels of human endometrial stromal cells treated with 4PPDOT. (C) Western blot bands of inflammation- related proteins in human endometrial stromal cells. (D) Immunoblot analysis of p-RELA, RELA, ERK1/2. (E) Western blot bands of autophagy related proteins in human endometrial stromal cells. (F) Immunoblot analysis of LC3B, ATG5, ATG7. (G) Western blot bands of apoptosis related proteins in human endometrial stromal cells. (H) Immunoblot analysis of c-PARP, BAX, CASP1, c-CASP3. (I) Flow cytometry was used to detect apoptosis after adding the 4PPDOT and melatonin, and apoptosis cells were measured. n = 3 independent biological replicates. Veh: vehicle treatment group; LPS: LPS treatment group; Mel+LPS: melatonin and LPS co-treatment group; Mel: melatonin treatment group; The data are presented as the mean ± SD. Levels of statistical significance for all data were determined by one-way ANOVA and Tukey’s test (* Indicates significant difference between the two groups; * p < 0.05; ** p < 0.01; *** p < 0.001).

    Article Snippet: Once cells were attached, HESCs were starved for 12 h in DMEM/F12, cells were treated with 1 μM Melatonin and 50 μg/mL LPS for 48 h. For experiments involving inhibitors, cells were incubated with inhibitors for 48 h. The following specific inhibitors were used: melatonin receptor antagonist 4-P-PDOT (MedChemExpress, Monmouth Junction, NJ, USA), and the METTL3-METTL14 complex inhibitor SAH (MCE, Monmouth Junction, NJ, USA).

    Techniques: Proliferation Assay, Western Blot, Flow Cytometry